Traws Pharma, Inc.
TRAW
Rank in Stocks
#31124
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage,... Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
Share Price
$0.24
Last synced: 2026-11-09
Market Cap
$3.69M
Change (1 day)
8.16%
Change (1 year)
-88.79%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Traws Pharma, Inc. (TRAW)
Category
Healthcare
Operating Margin for Traws Pharma, Inc. (TRAW)
Operating Margin as of November 2026 TTM: 0.00%
According to Traws Pharma, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -640.68%.
Operating Margin history for Traws Pharma, Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -640.68% | -97.07% |
| 2024 | -21,835.40% | 143.12% |
| 2023 | -8,981.42% | 3.42% |
| 2022 | -8,684.51% | 18.98% |
| 2021 | -7,299.12% | -32.54% |
| 2020 | -10,819.48% | 988.48% |
| 2019 | -994.00% | -47.57% |
| 2018 | -1,895.93% | -42.03% |
| 2017 | -3,270.27% | 665.17% |
| 2016 | -427.39% | 104.25% |
| 2015 | -209.25% | -97.37% |
| 2014 | -7,968.00% | 508.66% |
| 2013 | -1,309.11% | 2,614.31% |
| 2012 | -48.23% | -97.40% |
| 2011 | -1,854.27% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Traws Pharma, Inc.'s operating margin
What was Traws Pharma, Inc.'s operating margin in 2025?
In 2025, Traws Pharma, Inc.'s operating margin was -640.68%, compared with -21,835.40% in 2024.
How has Traws Pharma, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Traws Pharma, Inc.'s operating margin was highest in 2025 (-640.68%) and lowest in 2024 (-21,835.40%).
How does Traws Pharma, Inc.'s operating margin compare with similar companies?
Traws Pharma, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.